Zoetis Inc. has unveiled AI Masses, the latest AI-powered analysis technology incorporated into the Vetscan Imagyst® analyzer, enhancing its capabilities in veterinary diagnostics. This new feature provides fast and accurate in-clinic screening of common lymph node and skin/subcutaneous lesions within minutes, supporting veterinary professionals in making informed decisions. The innovative technology streamlines diagnoses and clinic workflows by detecting potentially neoplastic cells with high accuracy. With the addition of AI Masses, Vetscan Imagyst now offers seven unique testing applications, solidifying its position as the most capable veterinary AI analyzer globally. The new capability will be highlighted at the 40th World Veterinary Association Congress in conjunction with the AVMA Convention 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.